Vitex Acting On Inactine Viral Inactivation Technology Via Pentose Buy
This article was originally published in The Gray Sheet
V.I. Technologies (Vitex) is putting aside its own red blood cell virus inactivation system development plans in favor of the Inactine technology-based red cell program of Pentose Pharmaceuticals via a definitive $45 mil. stock-swap merger deal announced July 28.
You may also be interested in...
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.
Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.